Alzheimer’s medication catalyst for Genting

Earlier this week, Genting’s 20.3%-owned TauRx Pharmaceuticals said the initial phase three clinical trial data for its Alzheimer’s drug showed favourable results.

PETALING JAYA: The completion of clinical trials of an Alzheimer’s drug by Genting Bhd’s unit, TauRx Pharmaceuticals Ltd, will provide greater visibility to its path to profitability, according to analysts.

Earlier this week, Genting’s 20.3%-owned TauRx Pharmaceuticals said the initial phase three clinical trial data for its Alzheimer’s drug showed favourable results.